<DOC>
	<DOCNO>NCT01612286</DOCNO>
	<brief_summary>The investigator design study evaluate efficiency acute toxicity recombinant human endostatin ( endostar ) combine chemotherapy metastatic nasopharyngeal carcinoma ( NPC ) .</brief_summary>
	<brief_title>Endostar Combination With Chemotherapy Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>To evaluate progression free survival ( PFS ) , overall survival ( OS ) , Acute adverse reaction recombinant human endostatin ( endostar ) combine chemotherapy metastatic nasopharyngeal carcinoma ( NPC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Diagnosed metastatic NPC patient receive radiotherapy chemoradiotherapy least 6 month interval Have measurable lesion No dysfunction major organ Can understand study give sign informed consent certificate without history allergic reaction biological agent Pregnant lactating woman ; Women childbearing age without contraception Serious infection dysfunction major organ take antitumor drug period 30 day ahead clinical trial allergic Escherichia coli preparation Can n't understand study give sign informed consent certificate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Recombinant human endostatin</keyword>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>chemotherapy</keyword>
</DOC>